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Background: Recent data suggest that retinol-binding protein 4 (RBP4) gene
variants could be associated with a risk of obesity and its co-morbidities, such
as metabolic syndrome, which increases the risk of developing type 2 diabetes
mellitus and cardiovascular disease.
Objectives: The present study examined the potential association of RBP4
single nucleotide polymorphisms (SNPs) with childhood obesity and its
metabolic complications.
Methods: Four RBP4 SNPs, rs3758538 (3944A>C), rs3758539 (4406G>A),
rs12265684 (12177G>C) and rs34571439 (14684T>G), were genotyped in a
population of 180 Spanish Caucasian children (97 obese and 83
normal-weight children). Association of RBP4 SNPs with obesity, metabolic
risk factors (blood pressure, triglycerides, high-density lipoprotein cholesterol,
insulin resistance) and markers of vascular inflammation, such as
high-sensitive C-reactive protein (hs-CRP), was tested.
Results: We found SNP rs3758538 to be associated with obesity (p = 0.007).
Specifically, each copy of the minor allele C was associated with an increased
risk of obesity, by more than twofold, in respect of being homozygous for the
major allele A (odds ratio = 2.4; 95% confidence interval = 1.2–4.8). The
rs3758538 and rs34571439 RBP4 SNPs correlated with plasma RBP4 levels.
The SNPs rs12265684 and rs34571439 correlated with plasma triglyceride
levels. The rs34571439 was also associated to hs-CRP levels. Marginal
association of RBP4 SNPs with plasma high-density lipoprotein levels
(rs34571439), blood pressure (rs12265684) and insulin resistance (rs3758539)
was also observed.
Conclusions: These findings suggest that childhood obesity may be associated
with variations in RBP4 gene. The presence of selective SNPs in the RBP4
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Obesity-associated diseases, formerly considered to be
exclusively an ‘adult’ condition, are now growing
in children and can lead to a shortened lifespan.
Although the escalating rate of obesity is likely to
be a result of changes in human behavior and lifestyle,
the importance of genetic factors in the development
of co-morbidities, such as type 2 diabetes mellitus,
metabolic syndrome or fatty liver disease, among
others, is noteworthy (1).
It is well-established that adipokines, biologically
active factors secreted by adipose tissue, play an
important role in the development of obesity-related
complications not only in adults but also in children
and adolescents (2). One such adipokine is the retinol-
binding protein 4 (RBP4), a member of the lipocalin
family of proteins that transport vitamin A from the
liver to target tissues. RBP4 is synthesized primarily
in the liver and, to a lesser extent, in adipose tissue
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Fig. 1. Linkage disequilibrium between retinol-binding protein 4 single nucleotide polymorphism (RBP4 SNP) pairs, evaluated via the
Lewontin’s standardized coefficient D′. Values of D′ ranged between 0 and 1. A value of 0 for D′ indicates that the examined SNPs are
independent of each other, whereas a value of 1 demonstrates complete dependency.
and other organs such as kidney and ovaries (3).
RBP4 has been correlated with several conditions
related to obesity, such as type 2 diabetes mellitus
and metabolic syndrome (4, 5). Recently, our group
showed that increased plasma RBP4 levels might
potentially identify obese children at an increased risk
for developing co-morbidities, mainly because of its
association with markers of oxidative stress (6).
Given these facts, the RBP4 gene may represent a
susceptibility gene to obesity-related sequelae. In this
sense, some studies have reported that common vari-
ations in the RBP4 gene increase the risk of metabolic
disease in human. Specifically, rs3758538 (3944A>C)
and rs3758539 (4406G>A), both in the promoter 5′
flanking region; the intronic rs12265684 (12177G>C)
between Exons 4 and 5; and rs34571439 (14684T>G)
located in the 3′ untranslated region of the gene (Fig. 1)
have been shown to be linked to insulin resistance (7),
type 2 diabetes (8, 9) and several parameters of lipid
metabolism (10, 11) in adult populations. However,
limited and contradictory data exist regarding the
influence of RBP4 single nucleotide polymorphisms
(SNPs) in children and adolescents (12). At this
regard, the present study was conducted in children
and aimed to determine the association of the four
variants previously described of the RBP4 gene [SNPs
rs3758538, rs3758539, rs12265684 and rs34571439
(Table S1, Supporting Information)] with obesity and
development of related metabolic complications.
Patients and methods
Study subjects
The study population included 180 Caucasian chil-
dren (96 females) between 5 and 17 years of
age who were consecutively recruited from the
outpatient Gastroenterology and Nutrition Clinic of
the Department of Pediatrics, Dr. Peset Univer-
sity Hospital. The local Research Ethics Commit-
tee approved the study, and informed consent was
obtained from all parents and subjects. The body mass
index (BMI) z-score, based on age and sex, was calcu-
lated according to the WHO Child Growth Standards
(13). A total of 97 children presented with obesity
(defined as a BMI z-score ≥ 2), and 83 children pre-
sented with normal weight. Metabolic risk factors were
evaluated. Blood pressure (BP) was measured at the
time of consultation in the dominant arm, and the mean
arterial pressure {[(2 × diastolic BP) + systolic BP]/3}
was considered for analysis. Biochemical metabolic
syndrome components (lipid profile, glucose, insulin)
were determined by automated methods (Architect C
16000; Abbott Diagnostics, Abbott Park, IL, USA).
The Homeostasis model assessment for insulin resis-
tance (HOMA-IR) index was calculated as fasting
insulin levels (IU/l) x fasting glucose (mmol/L)/22.5.
Plasma RBP4 and high-sensitive C-reactive protein
(hs-CRP) levels were measured by immunonephelome-
try in a Beckman Image 800 analyzer (Beckman Coulter
Canada Inc, Mississauga, Canada). Exclusion criteria
for the study were the following: non-Caucasian ethnic-
ity, genetic or endocrine disorders and medication use.
Subjects were also excluded if there were symptoms or
signs of infectious or inflammatory illness, which was
confirmed by clinical history, physical examination and
laboratory tests. Clinical, anthropometric and analyti-
cal data of the included children are shown in Table S2.
Genotyping
The four SNPs of the RBP4 gene were genotyped in
the genomic DNA of all children. Genomic DNA was
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extracted from peripheral blood using the QIAamp
DNA Blood Mini Kit from Qiagen, (Izasa, Madrid,
Spain) according to the manufacturer’s protocol.
Genotyping of the RBP4 SNPs was performed by
real time PCR, using TaqMan® SNP Genotyping
on demand assays, which are commercially supplied
by Applied Biosystems (Life Technologies, Carlsbad,
CA, USA). The assays were performed according to
the manufacturer’s instructions. Briefly, each sample
reaction was composed of 2.5 μL of TaqMan®
Genotyping Master Mix from Applied Biosystems
(Life Technologies), 0.12 μL of TaqMan® probe assay,
and 2.5 μL of DNA sample at 5 μg/mL. The thermal
cycler conditions were as follows: an initial stage of
50◦C for 2 min, a second stage of 95◦C for 10 min and
a third stage consisting of 45 cycles of 95◦C for 15 sec
and 60◦C for 1 min. Thermal cycling and detection were
performed in a Fast-Real time PCR system 7900HT
from Applied Biosystems (Life Technologies).
Statistical analysis
Statistical tools for genotype and haplotype analysis
of SNPs (Hardy–Weinberg equilibrium, linkage
disequilibrium, genotype/haplotype distributions and
association tests) were provided by SNPStats software,
available in http://bioinfo.iconcologia.net/SNPstats/.
The Kolmogorov–Smirnov test was used for testing
normality, and skewed variables (such as hs-CRP)
were log-transformed prior to using parametric tests.
All tests were adjusted by age and gender. For associ-
ation with obesity, an unmatched case (obese)-control
(normal weight) design is assumed. The logistic regres-
sion analysis is summarized by genotype frequencies,
proportions, odds ratio (OR) and 95% confidence
interval (CI). For the association tests of quantitative
variables, a unique population was assumed and linear
regression models were used to assess the proportion
of variation in the response explained by the SNPs.
Data are presented as the means, standard error of
the mean, mean differences with respect to a reference
category (the most frequent genotype or haplotype),
and 95% CI of the differences. Five genetic models were
considered (codominant, dominant, recessive, additive
and overdominant). The Akaike information criterion
(AIC) and Bayesian Information Criterion (BIC) were
used to choose the genetic model that best fit the data.
The preferred model is that with the lowest AIC and
BIC values. Following Bonferroni correction, p-values
of ≤0.0125 were considered statistically significant,
and those between 0.05 and 0.0125 were regarded
as marginally significant. Haplotype association test
was performed in cases in which the association was
statistically significant for more than one SNP.
Linkage disequilibrium between RBP4 SNP pairs
was evaluated by means of Lewontin’s standardized
coefficient D′. Values of D′ ranged between 0 and 1. A
value of 0 for D′ indicates that the examined SNPs are
independent of each other, whereas a value of 1 indi-
cates that they are in complete linkage disequilibrium.
Results
Genotyping
Successful genotyping of the four RBP4 SNPs was
achieved in 100% of the samples. All genotype
frequencies were consistent with those expected from
Hardy–Weinberg equilibrium. We calculated the
linkage disequilibrium for each pair of SNPs. We
found that three of four SNPs (rs3758539, rs12265684
and rs34571439) were in strong linkage disequilibrium
(D′ statistic values approximately 0.90, p< 10−16) and
poorly related to the other SNP [the 5′-near gene
rs3758538 (Fig. 1)].
Association between RBP4 SNPs with obesity
and other metabolic risk factors
We analyzed the genotype effect of the four RBP4
SNPs on obesity (Table 1) and other variables related to
metabolic syndrome (carbohydrate metabolism, lipid
profile, BP) (Table 2). We found that SNP rs3758538
was associated with obesity and BMI z-score in an
additive model. Specifically, each copy of the C allele
was associated with an increased risk of obesity, by
more than twofold (p = 0.007) and with an increase of
0.81 points in the BMI z-score (p = 0.022) in respect
of being homozygous for the major allele A. For
the other SNPs, although we observed a higher BMI
z-score and an increase in the OR in homozygous minor
allele carriers with respect to the major allele carriers,
such association did not reach statistical significance.
Regarding lipid metabolism, we found three of four
SNPs (SNPs rs3758539, rs12265684 and rs34571439)
to be associated with triglyceride levels in the
dominant model. Individuals carrying the minor allele
(homozygous or heterozygous) had increased plasma
triglyceride levels with respect to those children
who were homozygous for the major allele. The
significance was mainly achieved for the intronic
SNP rs12265684. Children carrying the minor allele
C (GC and CC genotypes) had an increase of
18.5 mg/dL in triglyceride values compared with
those children who were homozygous for the major
allele G (p = 0.002). Significant results were also
obtained for SNP rs34571439 (p = 0.007), whereas
SNP rs3758539 was marginally associated (p = 0.017).
The non-coding SNP rs34571439 was the only SNP
to be marginally associated with plasma high-density
lipoprotein cholesterol (HDL-C) levels, under an
additive model. We found that each copy of the
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Table 1. Association of RBP4 SNPs with childhood obesity
SNP ID Genotype Normal weight n (%) Obese n (%) OR (95% CI) p-value* Best model†
rs3758538 A/A 70 (84.3) 69 (71.1) 2.4 (1.2–4.8) 0.007 Additive
A/C 13 (15.7) 23 (23.7)
C/C 0 (0) 5 (5.2)
rs3758539 G/G 52 (62.6) 57 (58.8) 2.5 (0.5–13.0) 0.24 Recessive
G/A 29 (34.9) 34 (35.0)
A/A 2 (2.4) 6 (6.2)
rs12265684 G/G 57 (68.7) 60 (61.9) 4.3 (0.5–37.5) 0.14 Recessive
G/C 25 (30.1) 32 (33.0)
C/C 1 (1.2) 5 (5.2)
rs34571439 T/T 56 (67.5) 60 (61.9) 5.3 (0.6–45.0) 0.07 Recessive
T/G 26 (31.3) 31 (32.0)
G/G 1 (1.2) 6 (6.2)
CI, confidence interval; OR, odds ratio; RBP4, retinol-binding protein 4; SNP, single nucleotide polymorphism.
*Following Bonferroni correction, p-values ≤ 0.0125 were considered statistically significant (in bold in the Table), and those
between 0.05 and 0.0125 were regarded as marginally significant.
†The Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC) were calculated to select the best inheritance
model for each specific polymorphism. The preferred model is that with the lowest AIC and BIC value. p-values ≤ 0.0125
were considered statistically significant (in bold in the Table).
G minor allele was associated with a decrease
of 2.7 mg/dL in HDL-C plasma values (p = 0.045)
compared with homozygous genotype for the major
allele T.
We found a significant (although marginally)
association between the SNP rs3758539 and insulin and
HOMA-IR values under a recessive model (p = 0.040).
Children who were homozygous AA had higher insulin
levels and HOMA-IR values than carriers of the major
allele G (GG and GA genotypes).
With respect to BP, we found that the SNPs
rs3758538 and rs12265684 were marginally associated
(p = 0.043 and p = 0.038, respectively) with mean arte-
rial pressure, minor allele carriers having higher values
of mean arterial pressure than major allele carriers.
Association between RBP4 SNPs and plasma
RBP4 and hs-CRP protein levels
The four SNPs studied showed association with plasma
RBP4 levels (Table 3), but only the SNPs rs3758538
and rs34571439 result in a significant contribution
in an additive model to higher RBP4 plasma levels.
Specifically, each copy of the minor allele C of
SNP rs3758538 produces an increase of 0.5 mg/dL
in RBP4 values compared with the levels of carriers
of homozygous major allele A. Similarly, in the case
of rs34571439 SNP, carriers of the minor allele G
(T/G, G/G) had an increase of 0.5 mg/dL of RBP4
plasma values compared with those of the T/T wild-
type homozygous subjects. We additionally performed
a haplotype association analysis considering these
two SNPs (Table S3). The haplotype with the minor
allele in the two SNPs (3944C, 14684G), which had
a frequency of 3%, is associated with an increase
of 1.4 mg/dL in serum RBP4 values compared with
the most common haplotype (3944A, 14684T) (95%
CI = 0.41–2.36 mg/dL, p = 0.006).
We also performed an association analysis between
RBP4 SNPs and the marker of inflammation hs-CRP
(Table 3). Linear regression analysis showed the four
SNPs to be associated with hs-CRP under a recessive
model. Individuals who were homozygous for the
minor allele had significantly higher hs-CRP levels
(increase of 0.40–0.50 mg/dL) compared with carriers
of major allele. However, significant association was
only achieved for rs34571439 SNP (p = 0.011).
Discussion
There is evidence of association of elevated plasma
RBP4 levels with obesity and insulin resistance (14,
15) although there are also other studies that have
been unable to establish these associations (16). Recent
research supports a relevant role of the RBP4 gene
in childhood and adult obesity (17, 18). However,
controversy remains regarding the role of RBP4 SNPs
underlying the risk for obesity and associated co-
morbidities (12, 16). In the current study, we sought
to investigate the relationship between variation in
the RBP4 gene and obesity and metabolic traits in
children. We found the SNP rs3758538 to be correlated
with obesity and higher BMI z-score. Carriers of the
minor allele C were associated with higher BMI z-
scores and a higher risk of obesity, according to an
additive model. To our knowledge, this is the first
report of an association of this SNP with childhood
obesity. The influence of the rs3758538 polymorphism
on obesity risk could be ascribed to its influence on
modulating RBP4 expression, with minor allele C
associated with a higher RBP4 expression and higher
risk of obesity. EnhancedRBP4 gene expression may be
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Table 2. Association of RBP4 SNPs with parameters of metabolic risk*
SNP ID Genotype n Mean (SEM)
Difference
(95% CI)† p-value‡ Best model
BMI z-score rs3758538 A/A 139 2.01 (0.20) 0.81 (0.12–1.50) 0.022 Additive
A/C 36 2.69 (0.41)
C/C 5 3.59 (0.53)
rs3758539 G/G 109 2.04 (0.21) 0.41 (−0.29–1.12) 0.14 Additive
G/A 63 2.29 (0.31)
A/A 8 3.48 (1.16)
rs12265684 G/G 117 2.06 (0.21) 0.48 (−0.15–1.10) 0.14 Additive
G/C 57 2.31 (0.31)
C/C 6 3.57 (1.53)
rs34571439 T/T 116 2.05 (0.20) 0.45 (−0.16–1.06) 0.14 Additive
T/G 57 2.31 (0.33)
G/G 7 3.52 (1.29)
Triglycerides (mg/dL) rs3758538 A/A 139 79.6 (3.5) −7.3 (−20.7–6.1) 0.29 Dominant
A/C–C/C 41 72.6 (4.4)
rs3758539 G/G 109 72.5 (3.0) 14.1 (2.5–25.6) 0.017 Dominant
G/A–A/A 71 86.6 (5.6)
rs12265684 G/G 117 71.8 (3.0) 18.5 (6.8–30.2) 0.002 Dominant
G/C–C/C 63 89.9 (5.8)
rs34571439 T/T 116 72.3 (3.0) 16.2 (4.6–27.9) 0.007 Dominant
T/G–G/G 64 88.6 (5.8)
HDL-C (mg/dL) rs3758538 A/A 139 49.7 (0.9) −2.5 (−6.0–1.1) 0.18 Dominant
A/C 36 46.9 (1.4)
C/C 5 49.8 (5.15)
rs3758539 G/G 109 49.8 (0.99) −1.6 (−4.2–0.9) 0.21 Additive
G/A 63 48.5 (1.26)
A/A 8 45.5 (4.06)
rs12265684 G/G 117 50.0 (1.0) −2.3 (−5–0.5) 0.10 Additive
G/C 57 48.0 (1.26)
C/C 6 44.3 (5.16)
rs34571439 T/T 116 50.2 (0.97) −2.7 (−5.3–−0.1) 0.045 Additive
T/G 57 47.9 (1.27)
G/G 7 43.4 (4.45)
HOMA-IR rs3758538 A/A 175 2.8 (0.1) 0.5 (−1.2–2.4) 0.54 Recessive
A/C–C/C 5 3.3 (0.5)
rs3758539 G/G 172 2.7 (0.1) 1.5 (0.1–3.0) 0.040 Recessive
G/A–A/A 8 4.2 (1.8)
rs12265684 G/G 174 2.8 (0.2) −0.5 (−2.2–1.1) 0.51 Recessive
G/C–C/C 6 2.2 (0.6)
rs34571439 T/T 173 2.8 (0.2) −0.3 (−1.8–1.2) 0.71 Recessive
T/G–G/G 7 2.5 (0.5)
Mean arterial
pressure (mm Hg)
rs3758538 A/A 175 82.6 (0.72) 8.8 (0.4–17.3) 0.043 Recessive
A/C–C/C 5 91.4 (3.1)
rs3758539 G/G 109 81.8 (0.90) 2.7 (−0.2–5.5) 0.07 Dominant
G/A–A/A 71 84.4 (1.2)
rs12265684 G/G 117 81.8 (0.8) 2.7 (0.2–5.2) 0.038 Additive
G/C 57 84.7 (1.4)
C/C 6 86.3 (1.9)
rs34571439 T/T 173 82.6 (0.7) 4.9 (−2.3–12.2) 0.18 Recessive
T/G–G/G 7 87.6 (2.0)
BMI, body mass index; CI, confidence interval; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model
assessment of insulin resistance; RBP4, retinol-binding protein 4; SEM, standard error of the mean; SNP, single nucleotide
polymorphism.
*To convert triglycerides to mmol/L multiply by 0.0113; HDL-C by 0.0259.
†Maximum significative difference between means.
‡Following Bonferroni correction, p-values ≤ 0.0125 were considered statistically significant (in bold in the Table), and those
between 0.05 and 0.0125 were regarded as marginally significant.
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Table 3. Association of RBP4 SNPs with RBP4 and hs-CRP plasma levels
SNP ID Genotype n Mean (SEM) Difference (95% CI)* p-value† Best model
RBP4 (mg/dL) rs3758538 A/A 139 4.25 (0.09) 0.51 (0.17–0.84) 0.004 Additive
A/C 36 4.77 (0.24)
C/C 5 5.22 (0.73)
rs3758539 G/G 109 4.23 (0.09) 0.38 (0.04–0.73) 0.031 Dominant
G/A–A/A 71 4.61 (0.17)
rs12265684 G/G–C/C 123 4.24 (0.10) 0.44 (0.08–0.80) 0.018 Overdominant
G/C 57 4.68 (0.17)
rs34571439 T/T 116 4.21 (0.10) 0.50 (0.15–0.85) 0.006 Dominant
T/G–G/G 64 4.70 (0.17)
hs-CRP (mg/L) rs3758538 A/A–A/C 175 1.84 (0.26) 0.49 (0.04–0.94) 0.033 Recessive
C/C 5 3.46 (1.18)
rs3758539 G/G–G/A 172 1.85 (0.27) 0.42 (0.06–0.77) 0.024 Recessive
A/A 8 2.56 (0.54)
rs12265684 G/G–G/C 174 1.84 (0.27) 0.50 (0.09–0.91) 0.019 Recessive
C/C 6 3.17 (0.72)
rs34571439 T/T–T/G G/G 173 1.83 (0.27) 0.50 (0.12–0.88) 0.011 Recessive
7 3.07 (0.62)
CI, confidence interval; hs-CRP, high-sensitivity C-reactive protein; RBP4, retinol-binding protein 4; SNP, single nucleotide
polymorphism.
*Maximum significative difference between means.
†Following Bonferroni correction, p-values ≤ 0.0125 were considered statistically significant (in bold in the Table), and those
between 0.05 and 0.0125 were regarded as marginally significant.
linked to adipogenic transcription factors that facilitate
the transport and storage of fatty acids (19) affecting
the size and recruitment of adipocytes.
However, the mechanism by which RBP4 influences
the occurrence of obesity and its co-morbidities
remains poorly understood. Previous reports suggested
that RBP4 affects glucose metabolism through
conferring insulin resistance (20). Subsequent studies
have demonstrated a correlation between high plasma
RBP4 levels and type 2 diabetes mellitus (21, 22).
However, other authors have failed to confirm this
finding, and some have even shown an inverse
correlation (23). In our work, we found only SNP
rs3758539 to be marginally associated with insulin
resistance under a recessive model, where individuals
carrying two copies of the minor allele A have higher
values for HOMA-IR than major allele carriers. Our
results agree with those of others who have reported
that homozygous carriers of the A allele of this SNP
are associated with an increased risk of type 2 diabetes
(7, 8, 24), whereas a study conducted in children (12)
has failed to find any association with carbohydrate
metabolism. This discrepancy may be due to higher
HOMA-IR values in children of our study. Therefore,
these individuals would be more likely to develop type
2 diabetes later in life.
Regarding lipid metabolism, we found association
between three SNPs (rs3758539, rs12265684 and
rs34571439) and triglyceride levels. Carriers of one or
two copies of the minor allele have higher triglyceride
values. There is growing evidence that RBP4 may play
a role in the pathophysiology of lipid homeostasis
through either hepatic production or catabolism of
very low-density lipoproteins (25). Thus, in turn, alleles
that increase RBP4 expression, such as the minor
allele G in rs34571439 could increase the susceptibility
to dyslipidemia. We have not found association of
triglyceride levels with rs3758538 contrary from a
previous study in Chinese population (10). In this
study, the variant rs3758538 exhibited association with
reduced plasma triglyceride levels. The same authors
reported a marginal association of C allele of rs3758538
with lower plasma RBP4 values. The reason for the
discrepancies with our results is unclear but ethnic
differences may be in cause. In addition, we also found
SNP rs34571439 to be marginally associated with
HDL-C levels, with minor allele G associated to lower
levels of HDL-C. Thus, the SNP rs34571439 could
provide valuable information about vascular risk asso-
ciated with atherogenic dyslipidemia, since the minor
allele G confers an increased risk of having higher
levels of triglycerides and lower levels of HDL-C. It
is noteworthy that RBP4 has been recently identified
as a HDL-C associated protein (26). It may influence
lipid metabolism and contributes to the formation
of small HDL-C that are related to cardiovascular
risk (27).
An important novel aspect of our study was the
finding that homozygous carriers of the minor allele
of the rs34571439 variant, that are associated with
higher RBP4 plasma levels, is also correlated with
higher levels of plasma C-reactive protein values. To
our knowledge, this is the first report of an association
between genetic variants of theRBP4 gene and hs-CRP
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plasma levels. Several works have found a correlation
between baseline elevations of hs-CRP levels and future
risk of coronary events (28). Furthermore, there is
growing evidence that RBP4 is involved in vascular
inflammation and risk of cardiovascular disease (29).
Recently, serum levels of RBP4 have also been
associated with the presence and severity of coronary
artery disease (30). It seems that increased RBP4
expression might directly contribute to the progression
of endothelial/vascular inflammation via activation of
NADPH oxidase and NF-κB pathways (31).
Taken together, these initial findings support
a role for RBP4 genomic variance to the risk of
childhood obesity and its metabolic complications.
This influence appears to be based on the effects of the
polymorphisms on plasma RBP4 levels. However, we
are aware of several limitations of our study. It should
be noted that the small sample size of our series does
not allow to draw firm conclusions. Furthermore,
some associations observed in the present study are
marginal and require further validation in a larger
series. By contrast, we have used the Bonferroni
correction that is highly restrictive, and the study in
pediatric patients, in the early stages of metabolic
syndrome, offers the possibility to assess potential
associations without confounders habitually present
in adults. Genetic studies in a larger and independent
pediatric cohort are needed. Thus, the relationship
between obesity, adipose RBP4 expression, circulating
levels of RBP4, dislipidemia and insulin resistance
needs to be evaluated in future studies.
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